secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001493152-25-005310
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu
----------------------------------------------------------------------

- Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.
- Prior UAB clinical data showed Ampligen + FluMist induced cross-reactive antibodies against H5N1, H7N9, H7N3.
- Pre-clinical work demonstrated 50-100% survival in mice challenged with H5N1 variants vs. 0-60% naive controls.
- AIM has engaged CRO Amarex for IND application and study management; seeking government/industry grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315225005310/0001493152-25-005310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315225005310/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer